Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (symbol: OM) is a pioneering medical technology company committed to revolutionizing the dialysis experience. The company’s primary product, Tablo, is an innovative dialysis machine designed to simplify and streamline the process of Renal Replacement Therapy. By focusing on a patient-centric approach, Outset Medical places patient care, ease of use, and cost-efficiency at the forefront of its operations.
The Tablo dialysis system is built with a user-friendly touchscreen display that offers step-by-step visual and conversational instructions, making it accessible to both patients and caregivers, regardless of their experience level. This intuitive design dramatically reduces the complexity and cost associated with traditional dialysis treatments. Tablo can be used across various settings, including hospitals, chronic care dialysis clinics, and at home, making it a versatile solution for renal care.
Outset Medical’s mission is to improve the care experience for patients, families, providers, and physicians, while also enhancing cost-efficiencies for healthcare providers. The company achieves this by combining expertise from different healthcare fields, fostering an environment of cross-disciplinary innovation. This approach has led to significant advancements in dialysis technology and patient care.
Recent achievements include regulatory approvals and partnerships aimed at expanding Tablo’s reach and improving its functionalities. Financially, Outset Medical has shown robust growth, supported by a dedicated team of professionals and continuous innovation in their product offerings. The company's efforts are geared towards giving people their time back by reducing the dialysis process's complexity and duration.
Stay updated with the latest developments and news about Outset Medical, Inc. to learn how this industry leader is transforming renal care.
Outset Medical, Inc. (NASDAQ: OM) will release its third-quarter 2021 financial results after the market closes on November 3, 2021. A conference call hosted by CEO Leslie Trigg and CFO Nabeel Ahmed will take place at 2:00 PM PT to discuss these results. The Tablo® Hemodialysis System, which simplifies and reduces costs associated with dialysis, exemplifies Outset's innovation in improving patient care. The system enables dialysis to be provided anywhere with integrated technology for data analytics and water purification.
Outset Medical, Inc. (NASDAQ: OM) announced its participation in two virtual investor conferences. The 2021 Virtual Wells Fargo Healthcare Conference is scheduled for September 9, 2021 at 10:20 a.m. PT, while the Morgan Stanley 19th Annual Global Healthcare Conference will take place on September 13, 2021 at 2:00 p.m. PT. Outset's Tablo® Hemodialysis System simplifies dialysis and is FDA-cleared for use in various settings. Live webcasts will be accessible on the Outset website.
Outset Medical, Inc. (Nasdaq: OM) reported a significant financial performance in Q2 2021, with net revenue increasing by 115% to $25.2 million compared to Q2 2020. The company's gross margin improved to 4.2% from (40.6%). Product revenue also surged by 113% to $20.6 million. Operating expenses rose to $31.0 million, and the net loss for the quarter was ($30.2 million), or ($0.66) per share. Outset raised its full-year 2021 revenue guidance to a range of $97 million to $100 million, a projected growth of 94% to 100%.
Outset Medical, Inc. (Nasdaq: OM) has appointed Nabeel Ahmed as the permanent Chief Financial Officer, effective immediately. Ahmed has been serving as the Interim CFO since July 2021 and has been with Outset since May 2020. His diverse experience in finance roles positions him well to lead the company during a pivotal time. Outset is known for its innovative Tablo Hemodialysis System, designed to reduce the cost and complexity of dialysis, facilitating care at various settings.
Outset Medical, Inc. (Nasdaq: OM) will release its second-quarter 2021 financial results on August 5, 2021, after market close. CEO Leslie Trigg and Interim CFO Nabeel Ahmed will host a conference call at 2:00 PM PT (5:00 PM ET) on the same day to discuss the results. Outset Medical is known for its innovative Tablo Hemodialysis System, which simplifies dialysis by integrating water purification and on-demand dialysate production, offering a portable solution for patients and healthcare providers.
Outset Medical (Nasdaq: OM) announces the departure of CFO Rebecca Chambers effective July 16, 2021, with Nabeel Ahmed stepping in as Interim CFO. The company predicts Q2 2021 net revenue between $24.5M to $25.0M, marking a remarkable growth of 109% to 113% year-over-year. Leslie Trigg, CEO, expresses gratitude towards Chambers for her contributions and confidence in Ahmed’s capabilities, given his extensive finance experience. Outset’s technology aims to simplify dialysis, enhancing patient care and operational efficiency.
Outset Medical, Inc. (Nasdaq: OM) has appointed Jean-Olivier Racine as Chief Technology Officer to lead advancements in its dialysis technology. Racine brings over two decades of experience, including roles at Amazon Web Services and expertise in health data services. He aims to enhance patient care and operational efficiency utilizing data-driven innovation. Outset’s FDA-cleared Tablo Hemodialysis System, known for its two-way wireless data transmission, allows real-time data sharing, aiding in analytics and service improvements. Racine's focus will support the unique capabilities of Tablo in transforming dialysis care.
Strive Health, a leader in value-based kidney care, and Outset Medical, Inc. (Nasdaq: OM), a dialysis innovator, have partnered to enhance kidney care. Strive aims to reduce hospitalizations for kidney disease patients using Outset's Tablo Hemodialysis System for home dialysis. The collaboration focuses on delivering high-quality patient care and integrating predictive analytics. Strive recently launched a new dialysis facility in Owensboro, KY, emphasizing holistic kidney management. This partnership aims to improve patient experience and accessibility to home dialysis services.
Satellite Healthcare and Outset Medical (Nasdaq: OM) announced a multi-year sales agreement to enhance home hemodialysis adoption across Satellite Healthcare's dialysis centers. The agreement involves the purchase of Tablo systems for home use and collaboration on educational initiatives to increase patient awareness. Satellite Healthcare aims to lead in at-home dialysis treatment, serving over 8,000 patients annually. Factors such as Medicare Advantage eligibility and increased telehealth usage are expected to drive growth in home dialysis.
Outset Medical, Inc. (Nasdaq: OM), a medical technology innovator, announced its management's participation in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 7:30am PT / 10:30am ET. The event will be available via live and archived webcast on Outset's investors page. Outset's flagship product, the Tablo Hemodialysis System, offers a groundbreaking solution to streamline dialysis delivery, ensuring it can be provided anywhere and anytime, significantly enhancing patient care and reducing costs.
FAQ
What is the current stock price of Outset Medical (OM)?
What is the market cap of Outset Medical (OM)?
What is Outset Medical, Inc.?
What product does Outset Medical offer?
How does the Tablo dialysis system work?
In what settings can Tablo be used?
What is the company's main mission?
Who can use the Tablo machine?
What is unique about the Tablo machine?
How does Outset Medical foster innovation?
What recent achievements does Outset Medical have?
How has Outset Medical performed financially?
